L-dopa co-drugs in nanostructured lipid carriers: A comparative study
- 1 March 2017
- journal article
- research article
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 72, 168-176
Abstract
No abstract availableKeywords
Funding Information
- Italian Ministry of University and Research (MiUR) (FIRB2010)
This publication has 49 references indexed in Scilit:
- Parkinson s disease a reviewFrontiers in Bioscience-Scholar, 2014
- The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part IJournal of Neuropathology & Experimental Neurology, 2007
- NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic ImplicationsAnnual Review of Pathology: Mechanisms of Disease, 2006
- Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughsNature Medicine, 2004
- Manganese increases L‐DOPA auto‐oxidation in the striatum of the freely moving rat: potential implications to L‐DOPA long‐term therapy of Parkinson's diseaseBritish Journal of Pharmacology, 2000
- History of levodopa and dopamine agonists in Parkinson's disease treatmentNeurology, 1998
- Neuroprotective Therapy for Parkinson's DiseaseExperimental Neurology, 1997
- Oxidative damage caused by free radicals produced during catecholamine autoxidation: Protective effects of O-methylation and melatoninFree Radical Biology and Medicine, 1996
- The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesisJournal of Neural Transmission, 1994
- Oxygen free radicals and Parkinson's diseaseFree Radical Biology and Medicine, 1991